Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report

This case report discusses the effective use of abrocitinib, a selective JAK1 inhibitor, in a 14-year-old patient with severe alopecia areata in the Philippines. The patient, who did not respond well to corticosteroids, showed significant hair regrowth with a daily dose of 100 mg abrocitinib, improving their SALT score from 98 to 3.3 over 7 months. The report highlights the necessity of sustained JAK1 inhibition, as reducing the dosing frequency led to a relapse. It suggests that future research should aim to optimize pediatric dosing strategies to ensure efficacy, safety, and tolerability for long-term treatment.